{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
USAN:LYSOSTAPHIN [USAN]
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Investigational
Source:
NCT01195948: Phase 1/Phase 2 Interventional Completed Uveitis
(2010)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:tefibazumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:baloramotide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03334500: Early Phase 1 Interventional Active, not recruiting Prostate Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
USAN:CERGUTUZUMAB [USAN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:efizonerimod alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
NCT01585259: Phase 1/Phase 2 Interventional Completed Non-ST Segment Elevation Myocardial Infarction
(2012)
Source URL:
Class:
PROTEIN